Congressman Dan Meuser, who represents Pennsylvania’s 9th Congressional District, posted a series of statements on social media addressing recent political developments and policy actions. His comments focused on the ongoing government shutdown, Democratic leadership’s response, foreign affairs involving Israel and Hamas, as well as updates regarding prescription drug pricing.
On October 10, 2025, Meuser announced his appearance on Newsline via Newsmax to discuss several pressing issues. He wrote: “I’ll be on Newsline on @NEWSMAX today at 1:15 PM! Make sure to tune in to hear about how the government shutdown is hurting everyday Americans, President Trump’s peace deal between Israel & Hamas, and the recent indictment of Letitia James for mortgage fraud.”
Later that day, he criticized Democratic leaders’ handling of the government shutdown. In a post dated October 10, 2025, Meuser stated: “Democrats are putting politics before the American people, plain and simple.
Every word out of Democrat leadership on this shutdown, from Schumer to Jeffries, has been false. They voted to shut down the government, hurting small businesses, putting military pay at risk, and”
The following day brought an update regarding pharmaceutical pricing policy. On October 11, 2025, Meuser commented: “Today, @POTUS announced a major agreement with @AstraZeneca, who will now lower prescription drug costs for Medicare and other major pharmaceuticals at a steep discount directly to consumers through TrumpRx. In addition to offering prescription drugs at lower costs to consumers,”
The backdrop for these remarks includes ongoing disputes over federal budget negotiations leading to partial government shutdowns—a recurring issue in U.S. politics that often impacts public services and employee paychecks. Congressman Meuser’s district encompasses much of northeastern Pennsylvania.
Prescription drug affordability has been a significant concern for many Americans in recent years as policymakers debate strategies for lowering costs across Medicare and private markets.
